Alpna Seth - Seagen Director

SGEN
 Stock
  

USD 180.11  3.17  1.79%   

  Director
Dr. Alpna Seth Ph.D., is Independent Director of Seattle Genetics, Inc., since March 2018. From July 2017 to January 2019, Dr. Seth served as the Chief Operating Officer of Vir Biotechnology, Inc., a publiclytraded biopharmaceutical company. Prior to joining Vir in July 2017, Dr. Seth was Senior Vice President and Global Head of the Biosimilars Global Business Unit for Biogen, Inc. headquartered in Zug, Switzerland since 2014. For the period from 1998 through July 2017, Dr. Seth held a range of leadership roles at Biogen in business development, drug development and commercial, including founding Managing Director of Biogen Idec India and Program Executive for several of Biogens major crossfunctional drug development programs and product launches. Dr. Seth serves as a member of the board of directors of BioTechne Corporationrationration, a publiclytraded biotechnology company. Dr. Seth holds a Ph.D. in Biochemistry and Molecular Biology from University of Massachusetts Medical School and conducted her postdoctoral research at Harvard University in Immunology and Structural Biology, both as a Howard Hughes Medical Institute Fellow. She is also a 2002 graduate of the Advanced Management Program at Harvard Business School. Dr. Seth brings a breadth of experience in drug development, commercial, international operations and general management.
Age: 54  Director Since 2018      
425 527-4000  www.seattlegenetics.com

Alpna Seth Latest Insider Activity

Tracking and analyzing the buying and selling activities of Alpna Seth against Seagen stock is an integral part of due diligence when investing in Seagen. Alpna Seth insider activity provides valuable insight into whether Seagen is net buyers or sellers over its current business cycle. Note, Seagen insiders must abide by specific rules, including filing SEC forms every time they buy or sell Seagen'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Seagen Management Efficiency

Seagen Inc has return on total asset (ROA) of (11.45) % which means that it has lost $11.45 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (21.47) %, meaning that it created substantial loss on money invested by shareholders. Seagen management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Investment is estimated to slide to -22.46. The value of Return on Average Assets is estimated to slide to -18.85. Seagen Asset Turnover is quite stable at the moment as compared to the past year. The company's current value of Asset Turnover is estimated at 0.42. Tangible Assets Book Value per Share is expected to rise to 5.74 this year, although the value of Revenue to Assets will most likely fall to 0.41.
The company currently holds 67.27 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Seagen Inc has a current ratio of 5.12, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Seagen until it has trouble settling it off, either with new capital or with free cash flow. So, Seagen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Seagen Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Seagen to invest in growth at high rates of return. When we think about Seagen's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

Kunal KashyapMereo Biopharma Group
N/A
Gongda YaoDaqo New Energy
2018
Bradley AlfordPerrigo Company
2017
Peter BainsMereo Biopharma Group
N/A
Robert ScullyZoetis Inc Cl
2013
James WalshTrinity Bio ADR
2015
Scott GottliebPfizer Inc
2019
Ray RobinsonAvnet Inc
2000
Avid ModjtabaiAvnet Inc
2014
Kerry ClarkAvnet Inc
2012
William SteereZoetis Inc Cl
2013
Susan DesmondHellmannPfizer Inc
2020
Rory NealonTrinity Bio ADR
2007
Anders EkblomMereo Biopharma Group
N/A
Richard JonesMereo Biopharma Group
2017
Willie ReedZoetis Inc Cl
2014
James KiltsPfizer Inc
2007
Michael WyzgaMereo Biopharma Group
2019
Stephen SangerPfizer Inc
2009
Dan LittmanPfizer Inc
2018
Clinton SeversonTrinity Bio ADR
2008
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. Seagen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2675 people. Seagen Inc (SGEN) is traded on NASDAQ Exchange in USA and employs 2,675 people.

Seagen Inc Leadership Team

Elected by the shareholders, the Seagen's board of directors comprises two types of representatives: Seagen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Seagen. The board's role is to monitor Seagen's management team and ensure that shareholders' interests are well served. Seagen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Seagen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pinkston Peggy, Senior Director - Corporate Communications
David Gryska, Independent Director
Roger Dansey, Chief Medical Officer
Vaughn Himes, Executive VP of Process Sciences and Technical Operations
Daniel Welch, Independent Director
Felix Baker, Lead Independent Director
Srinivas Akkaraju, Independent Director
Alpna Seth, Director
Nancy Simonian, Independent Director
Marc Lippman, Independent Director
Peggy Pinkston, IR Contact Officer
Jonathan Drachman, Chief Medical Officer and Executive Vice President Research and Development
Jean Liu, Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
Robert Lechleider, Senior Vice President - Clinical Development
Clay Siegall, Co-Founder, Chairman, CEO and Pres
Robin Taylor, Chief Commercial Officer
Darren Cline, Executive Vice President - Commercial
Dennis Benjamin, Senior Vice President - Translational Research
Eric Dobmeier, COO, Corporate Secretary
John Orwin, Director
Todd Simpson, CFO and Principal Accounting Officer
John McLaughlin, Independent Director

Seagen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Seagen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Seagen without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Rebalancing Now

   

Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
All  Next Launch Module

Currently Active Assets on Macroaxis

Additionally, take a look at World Market Map. Note that the Seagen Inc information on this page should be used as a complementary analysis to other Seagen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Seagen Stock analysis

When running Seagen Inc price analysis, check to measure Seagen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seagen is operating at the current time. Most of Seagen's value examination focuses on studying past and present price action to predict the probability of Seagen's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Seagen's price. Additionally, you may evaluate how the addition of Seagen to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Is Seagen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seagen. If investors know Seagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
5.23
Market Capitalization
32.6 B
Quarterly Revenue Growth YOY
0.28
Return On Assets
-0.11
Return On Equity
-0.21
The market value of Seagen Inc is measured differently than its book value, which is the value of Seagen that is recorded on the company's balance sheet. Investors also form their own opinion of Seagen's value that differs from its market value or its book value, called intrinsic value, which is Seagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seagen's market value can be influenced by many factors that don't directly affect Seagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seagen's value and its price as these two are different measures arrived at by different means. Investors typically determine Seagen value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.